



March 10, 2008

Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
805.447.1000
www.Amgen.com

Via Electronic Transmission

The Honorable Senator Charles E. Grassley
Ranking Member, Finance Committee
United States Senate
Washington, D.C. 20510-6200

Re: Your letter of February 26, 2008

Dear Senator Grassley:

Thank you for your letter of February 26, 2008.

Amgen's mission is to serve patients. We do this by developing human therapeutics, and we also do this by supporting the training and education of physicians and other healthcare professionals. I am proud of the support that Amgen provides to medical organizations to further the education of health care professionals and to support the responsible practice of medicine. I am therefore happy to agree to voluntarily disclose the donations and grants that Amgen's U.S. Medical Education Department makes to support these educational activities as well as the charitable donations made by the Amgen Foundation.

Our team is working diligently to determine exactly how to achieve this objective in the most timely and efficient manner and I expect to be in a position to follow up with you shortly to describe the information that we will be disclosing and the timeframe in which we expect to be making our first disclosure. We will also seek to set up a meeting with a member of your staff in the next two weeks in order to further discuss this matter.

Finally, as an example of our efforts to move toward greater transparency I want to draw your attention to the fact that Amgen posts dozens of our policies and practices on our external web site on a series of issues such as ethical research, responsible marketing practices and our business conduct, just to mention a few. To view the postings please see: http://www.amgen.com/about/amgen_policies.html where you will also find our existing policy of disclosing the list of all guideline-developing bodies to whom Amgen has provided financial support. As a condition of providing financial support, Amgen requires by contract that guideline-developing bodies publicly disclose that they receive funding from Amgen. For more information on this specific policy please see: http://www.amgen.com/media/clinical_trial_support_policy.html.

Please feel free to contact me if you have any questions or comments regarding this matter.

Yours sincerely,

Kevin W. Sharer
Chairman, President and C.E.O.